Recommended Next-Line Therapy for Follicular Lymphoma
For second-line therapy in relapsed/refractory follicular lymphoma, the preferred regimens include bendamustine + obinutuzumab or rituximab (if not previously treated with bendamustine), CHOP + obinutuzumab or rituximab, lenalidomide + rituximab, or tafasitamab + lenalidomide + rituximab for patients with ≥1 prior systemic therapy including an anti-CD20 monoclonal antibody. 1
Treatment Selection Algorithm
Step 1: Assess Prior Therapy and Response Duration
If you had a long response to first-line therapy:
- Consider retreating with the same regimen used initially, as long as it's not the immediate prior line 1
- This approach is reasonable when the unmaintained response lasted ≥12 months
If you had a short response or are refractory to first-line therapy:
- Switch to an agent with a different mechanism of action 1
- Do not repeat the therapy used in the immediate prior line
Step 2: Select Second-Line Regimen Based on Patient Factors
Preferred second-line options (in order of consideration):
Tafasitamab + lenalidomide + rituximab - This is now a preferred option based on the inMIND study for patients who are candidates for lenalidomide + rituximab and have received ≥1 prior systemic therapy including an anti-CD20 antibody 1
Bendamustine + obinutuzumab or rituximab - Avoid if previously treated with bendamustine 1
CHOP + obinutuzumab or rituximab - Appropriate for patients needing more intensive therapy 1
CVP + obinutuzumab or rituximab - Consider for less fit patients 1
Lenalidomide + rituximab - Effective option, now can be enhanced with tafasitamab 1
Step 3: Special Considerations for Older or Infirm Patients
If none of the standard therapies are expected to be tolerable:
- Rituximab monotherapy (375 mg/m² weekly for 4 doses) - preferred 1
- Tazemetostat (irrespective of EZH2 mutation status) 1
Step 4: Maintenance Therapy After Second-Line
After achieving response:
- Rituximab maintenance: 375 mg/m² every 12 weeks for 2 years (Category 1 recommendation) 1
- For rituximab-refractory disease: Obinutuzumab maintenance (1 g every 8 weeks for 12 doses) 1
Critical Pitfalls to Avoid
Loss of CD19 expression: The panel emphasizes that tafasitamab + lenalidomide + rituximab may lead to loss of CD19 expression, which could impact future CAR T-cell therapy efficacy. Re-biopsy to confirm CD19 positivity is mandatory prior to initiating CD19-directed CAR T-cell therapy 1
Bendamustine re-exposure: Do not use bendamustine-containing regimens if the patient was previously treated with bendamustine, as this negatively impacts response rates 1
Third-Line and Beyond
If no improvement 2-4 weeks after combined second-line therapy:
- Consider rituximab for antibody-mediated disease 1
- Consider cyclophosphamide for cell-mediated disease 1
- Loncastuximab tesirine + rituximab is being evaluated in phase II trials for relapsed/refractory FL after ≥1 prior treatment 1
Stem cell transplantation options:
- High-dose therapy with autologous stem cell rescue remains an option 2
- Allogeneic stem cell transplant for highly selected patients 2
The key principle is switching mechanism of action after treatment failure while considering the patient's fitness, prior bendamustine exposure, and future treatment options including potential CAR T-cell therapy.